Dr. Lance A. Rudolph, MD

Dr. Rudolph practices at New Mexico Clinical Research & Osteoporosis Center, Inc in Albuquerque, New Mexico.

Dr. Rudolph's NPI, 1376502997, was assigned on March 22, 2006. Dr. Rudolph graduated from University of Southern California Keck School of Medicine in 1974. Dr. Rudolph holds New Mexico license 83-104.

Dr. Rudolph's primary practice is New Mexico Clinical Research & Osteoporosis Center, Inc, at 300 Oak NE St, Albuquerque, NM 87106 in Bernalillo County. The practice phone is (505) 855-5525.

Dr. Rudolph's primary practice is New Mexico Clinical Research & Osteoporosis Center, Inc in Albuquerque, New Mexico. Dr. Rudolph is also affiliated with Presbyterian Hospital. The medical group on file is New Mexico Clinical Research & Osteoporosis Center. Dmand AI also links Dr. Rudolph to 3 more hospitals, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rudolph practices, 6 sites in all. Vendor and product names are available with a free account.

Internal medicine is Dr. Rudolph's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Rudolph is licensed in New Mexico.

CMS data shows 55,200 Medicare services from Dr. Rudolph across 18 procedure codes in 2024, for 1,119 Medicare patients. Medicare paid $988,795 for them. Every service was in an office.

CMS counts 1,119 Medicare patients who saw Dr. Rudolph in 2024. The largest group is 65 to 74, with 527 patients. 75% of them have osteoporosis, and 67% have high cholesterol. 3% are also on Medicaid. Their average risk score is 0.92, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Rudolph's median patient age at 74, with 86% women.

In 2024, Dr. Rudolph wrote 5,281 Medicare Part D claims for 513 patients. 85% of them were for generic drugs. CMS names the drug for 4,586 of them, across 90 drugs with 11 or more claims each, at $423,555 in total drug cost. In 2023, CMS named 4,507 claims across 99 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 69 out of 100 for Dr. Rudolph for performance year 2024, reported as part of a group. Dr. Rudolph accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rudolph as offering telehealth.

Dmand AI links 1 paper to Dr. Rudolph.

Dmand AI links Dr. Rudolph to 3 clinical trials. Conditions studied include Fibromyalgia, Muscular Diseases and Sjogren's Syndrome. Daiichi Sankyo sponsors the most, 2. Open Payments lists research payments to Dr. Rudolph that name 16 trials.

CMS Open Payments shows 351 general payments to Dr. Rudolph from 28 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 85% of the total. Amgen Inc. paid the most, $1,601. It also lists 115 research payments totaling $121,562 from 2016 to 2024, naming 16 clinical trials.

Dr. Rudolph graduated from University of Southern California Keck School of Medicine in 1974.